Burford Brothers Inc. Grows Stock Holdings in Novo Nordisk A/S $NVO

Burford Brothers Inc. increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 7.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,826 shares of the company’s stock after purchasing an additional 745 shares during the quarter. Burford Brothers Inc.’s holdings in Novo Nordisk A/S were worth $747,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Copeland Capital Management LLC raised its holdings in shares of Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after acquiring an additional 255 shares in the last quarter. North Capital Inc. bought a new position in Novo Nordisk A/S in the 1st quarter worth $27,000. Stone House Investment Management LLC purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth about $30,000. Disciplina Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 297 shares in the last quarter. Finally, Spirit of America Management Corp NY bought a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at about $35,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $54.41 on Friday. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $118.26. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $242.93 billion, a P/E ratio of 14.95, a PEG ratio of 2.50 and a beta of 0.68. The stock’s 50 day moving average is $56.24 and its 200 day moving average is $62.72.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s payout ratio is 22.53%.

Analysts Set New Price Targets

Several analysts have commented on NVO shares. Morgan Stanley lowered shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and lowered their price objective for the stock from $59.00 to $47.00 in a report on Monday, September 29th. Weiss Ratings reissued a “hold (c)” rating on shares of Novo Nordisk A/S in a research report on Tuesday, October 14th. Rothschild & Co Redburn upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 16th. Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $76.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.